LITS vs LIXT

Lite Strategy, Inc. vs Lixte Biotechnology Holdings, I — Valuation Comparison 2026

LITS

Biotechnology
Lite Strategy, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$1.02
Last close
Models
9/13
Active
VS

LIXT

Biotechnology
Lixte Biotechnology Holdings, I
Quality
4.2
out of 10
Value Trap
6
SAFE
Price
$5.99
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType LITS Fair ValueLITS Upside LIXT Fair ValueLIXT Upside
Bayesian DCF Intrinsic $0.32 -68.3% $1.66 -72.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.81 +77.0% $0.71 -88.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LITS vs LIXT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LITS vs LIXT — Which Stock Is More Undervalued?

LITS scores higher with a 6.5/10 quality rating vs LIXT's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lite Strategy, Inc. (LITS) and Lixte Biotechnology Holdings, I (LIXT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LITS currently trades at $1.02 with a QOC of 6.5/10, while LIXT trades at $5.99 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).